Category Archives: Cancer Treatment

Oncotarget Set To Compile the Biggest Science Journal Index of Research

Oncotarget is a free biomedical journal published online that covers various disciplines centered on the medical field. The journal provides a platform for scientific papers to be published online to make scientific research findings widely available.The platform has proved useful in bridging the many branches of biomedical specialties, especially through reviews. Due to the readily available research data, the fight against various disease has been bolstered through the application of researched clinical sciences. Oncotarget is a result of scientists who are bent on advancing science and are on a mission to eradicate diseases and promote a disease-free life.Due to a large number of scientific research articles published, the papers are indexed and archived to make them readily available.

This indexing allows access to medical practitioners, researchers and even the general public to quickly access what they need. To achieve this indexing process faster, Oncotarget is going to be publishing two journal issues every week. These problems appear in PubMed where they are numbered to faster reference.Oncotarget publishes research beyond the current scope of oncology and extends to fields such as aging. Papers have been posted to show the results of experiments in slowing down again in human beings. The interest in delaying aging has grown as evidence has pointed to it as a means of preventing the chronic diseases that come about with age.To delay aging, the essential pathways need to be identified and the measures to counter the process defined.

At present, there are pharmacological, dietary and behavioral interventions have been identified and put in place for further research. Drugs that target various gene pathways have also been developed for testing.The interventions that are currently being on tested on human beings to research about their effects on the lifespan include; mimicking dietary restrictions such as fasting and restricting proteins in the diet. Some of the best drugs being tested on their effectiveness in delaying aging include; according to Oncotarget, those which have been proven effective in inhibiting mTOR-S6K pathways. The journal also reports that drugs which activate AMPK or specific sirtuins are showing promise in the quest to delay aging in humans.

Functions of Oncortarget Medical Journal and Mikhail Blagosklonny

Impacts Journals first published Oncotaget in 2010. It is peer reviewed on a weekly basis to cover all the issues on oncology. It is also an international and open access medical journal. The two most influential editors in chief of Oncotarget are Andrei V.Gukdov and Mikhail Blagosklonny. The journal is written in English. Oncotarget mainly focuses on the pathological basis in all types of cancers. They also cover issues on therapy and probable treatment to assist in the management of cancer.

The medical journal also focuses on the effects of management programs and ways of administering new therapeutic agents. They publish on how people can live a quality life, experience satisfaction, and adhere to the protocols. They help the general public to explore the evidence on the existing treatment and therapies and explain how they can improve the possible outcomes. They also provide ways in which the patients and healthcare staff define the usage regarding acceptance and ultimate intake. Oncotaget also carries out studies on oncology in order to cover various issues in cell biology, cardiology, neuroscience, metabolism, endocrinology, and all areas in pharmacology. It is also important to note that the popularity of Oncotarget has been gained because of their punctuality, constructive, insightful, multiple peer reviews, and assisting the authors to improve the impact of the research.

It is important to note that each paper is usually published on special demand. It also covers the traditional multidisciplinary journal. The research is published online. The mission of the medical journal is to make the scientific results widely and rapidly available to many people. The mission of Oncortarget is to maximize the impact of issues in research to an excellent and insightful review. Oncortaget has prominent and professional scientists. It also helps the researchers to contribute to the growth of science. The target of the journal is to help the general public to live life without any cases of diseases. Another point to note is that the success of the medical journal is as a result of the extension of the research beyond oncology.

To know more click here

Cancer Pioneer Eric Lefkowsky: It’s in the Details

Ask Tempus CEO Eric Lefkowsky about the missing link in cancer treatment, and he’ll tell you: We need more data. After all, Lefkowsky co founded Tempus in order to make cancer treatment more effective.

As Lefkowsky explained in San Diego at the Fortune Brainstorm Health conference recently, very few sources in medicine combine patient genomic information with therapeutic data. This means that clinicians presently lack the full knowledge of each patient’s course of treatment and how he or she responds to that treatment to learn more: click here.

Researchers need to look at why a certain percentage of a group responds to a treatment for a disease, such as breast cancer, but the others in the group don’t, Lefkowsky explains. Perhaps the non-responders have another pre-existing condition, such as diabetes, that prevents treatment from being effective. Or maybe those members of the group take medications that interfere with the effectiveness of the treatment being researched.

Lefkofsky, also co-founder of Groupon, started Tempus after his wife, Liz, received the diagnosis of breast cancer. He realized during that harrowing time of going to clinics that oncologists don’t get enough data to do their jobs properly, particularly when it comes to data describing how a given treatment works for a given patient group.

Tempus, a technology company, seeks to insert such data into each patient’s electronic medical record. This way, the practitioner can more clearly find connections between treatments leading to desirable results.

In addition to co-founding Tempus and Groupon, the industrious Lefkowsky also co-founded Lightbank, Uptake Technologies, Mediaocean, Echo Global Logistics and InnerWorkings. He formed the Lefkofsky Family Foundation, a private charity, with Liz in 2006. Lefkofsky serves as a trustee on many boards, including that of Lurie Children’s Hospital of Chicago, and he chairs the board of trustees of Chicago’s Steppenwolf Theatre Company. An adjunct professor at the University of Chicago, Lefkowsky has also authored the book Accelerated Disruption. He received his law degree from the University of Michigan Law School.

For more information about Eric Lefkowsky, connect with him on LinkedIn or Facebook and follow him on Twitter (@lefkofsky).